Novo shares fall after weight-loss drug price deal

Investing.com -- Shares of Novo Nordisk are down 2.5% on Friday after the Trump administration announced agreements with the Danish drugmaker and Eli Lilly to cut prices for GLP-1 drugs used to treat diabetes and obesity.

Novo’s American Depository Receipts (ADRs) were down 0.8% in premarket trading.

Under the deal, both companies will reduce prices on GLP-1 drugs for diabetes and other approved uses to $245 per month.

Direct-to-consumer GLP-1 injectables will start at an average of $350, declining to $250 over the next two years. If approved, GLP-1 tablets will be priced at $149 for direct purchases.

Novo Nordisk will lower prices across all Wegovy and Ozempic medicines and commit an additional $10 billion to U.S. investment, according to reports.

The administration said lower prices will begin no later than January for direct-to-consumer sales, mid-2026 for Medicare, and progressively for Medicaid as states opt in.

Under the plan, GLP-1 drugs for obesity will be priced at $245 in Medicare and Medicaid, while diabetes versions will carry a $50 co-pay.

All future drug launches by both companies will follow “most favored nation” pricing across commercial, Medicare, Medicaid, and cash markets.

Nearly all primary care drugs are expected to be available at U.S. net prices when the Trump RX program launches in early 2026.

Related articles

Novo shares fall after weight-loss drug price deal

Natural Gas: Consolidation Could Set Stage for Breakout Above $3.20 Barrier

Gold: Will Safe-Haven Demand Push Yellow Metal Even Higher?

View Comments